c-myc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3

EMBO Journal

Volumn 25, Issue 24, 2006, Pages 5805-5815

  Sutherland, Kate D ^a,b   Vaillant, François ^a   Alexander, Warren S ^a   Wintermantel, Tim M ^c   Forrest, Natasha C ^a   Holroyd, Sheridan L ^a   McManus, Edward J ^a   Schutz, Gunther ^c   Watson, Christine J ^d   Chodosh, Lewis A ^e   Lindeman, Geoffrey J ^a   Visvader, Jane E ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; c myc; Mammary; Socs3; Stat3

Indexed keywords

PROTEIN BAX; PROTEIN P53; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR E2F1;

ANIMAL CELL; APOPTOSIS; ARTICLE; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE TARGETING; LACTATION; MAMMARY GLAND; MEDIATOR; MOUSE; NONHUMAN; ONCOGENE C MYC; PREGNANCY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL;

ANIMALS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; GENE DELETION; GENE TARGETING; INTEGRASES; LACTATION; LEUKEMIA INHIBITORY FACTOR; MAMMARY GLANDS, ANIMAL; MATRIX METALLOPROTEINASES; MICE; MODELS, BIOLOGICAL; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 33845710152     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/sj.emboj.7601455     Document Type: Article

References (61)

1. Abell K, Bilancio A, Clarkson RW, Tiffen PG, Altaparmakov AI, Burdon TG, Asano T, Vanhaesebroeck B, Watson CJ (2005) Stat3-induced apoptosis requires a molecular switch in PI(3)K subunit composition. Nat Cell Biol 7: 392-398
2. Alexander WS, Hilton DJ (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22: 503-529
3. Andres AC, van der Valk MA, Schonenberger CA, Fluckiger F, LeMeur M, Gerlinger P, Groner B (1988) Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. Genes Dev 2: 1486-1495
4. Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, Chodosh LA (2005) Developmental stage determines the effects of MYC in the mammary epithelium. Development 132: 1147-1160
5. Bowman T, Broome MA, Sinibaldi D, Wharton W, Pledger WJ, Sedivy JM, Irby R, Yeatman T, Courtneidge SA, Jove R (2001) Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. Proc Natl Acad Sci U S A 98: 7319-7324
6. Cartwright P, McLean C, Sheppard A, Rivett D, Jones K, Dalton S (2005) LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132: 885-896
7. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ (1999) Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13: 2604-2616
8. Clarkson RW, Boland MP, Kritikou EA, Lee JM, Freeman TC, Tiffen PG, Watson CJ (2006) The genes induced by signal transducer and activators of transcription (STAT)3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 20: 675-685
9. Cory S, Huang DC, Adams JM (2003) The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 22: 8590-8607
10. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS (2003) SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545
11. D'Cruz CM, Gunther EJ, Boxer RB, Hartman JL, Sintasath L, Moody SE, Cox JD, Ha SI, Belka GK, Golant A, Cardiff RD, Chodosh LA (2001) c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med 7: 235-239
12. Egle A, Harris AW, Bouillet P, Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101: 6164-6169
13. Eisenman RN (2001) Deconstructing myc. Genes Dev 15: 2023-2030
14. Fata JE, Leco KJ, Voura EB, Yu HY, Waterhouse P, Murphy G, Moorehead RA, Khokha R (2001) Accelerated apoptosis in the Timp-3-deficient mammary gland. J Clin Invest 108: 831-841
15. Harris J, Stanford PM, Sutherland K, Oakes SR, Naylor MJ, Robertson FG, Blazek KD, Kazlauskas M, Hilton HN, Wittlin S, Alexander WS, Lindeman GJ, Visvader JE, Ormandy CJ (2006) Socs2 and Elf5 mediate prolactin-induced mammary gland development. Mol Endocrinol 20: 1177-1187
16. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20
17. Helman D, Sandowski Y, Cohen Y, Matsumoto A, Yoshimura A, Merchav S, Gertler A (1998) Cytokine-inducible SH2 protein (CIS3) and JAK2 binding protein (JAB) abolish prolactin receptor-mediated STAT5 signaling. FEBS Lett 441: 287-291
18. Hennighausen L, Robinson GW (2005) Information networks in the mammary gland. Nat Rev Mol Cell Biol 6: 715-725
19. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T (1999) STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 189: 63-73
20. Krempler A, Henry MD, Triplett AA, Wagner KU (2002) Targeted deletion of the Tsg101 gene results in cell cycle arrest at G1/S and p53-independent cell death. J Biol Chem 277: 43216-43223
21. Kritikou EA, Sharkey A, Abell K, Came PJ, Anderson E, Clarkson RW, Watson CJ (2003) A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland. Development 130: 3459-3468
22. Kubo M, Hanada T, Yoshimura A (2003) Suppressors of cytokine signaling and immunity. Nat Immunol 4: 1169-1176
23. Lafleur MA, Handsley MM, Edwards DR (2003a) Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5: 1-39
24. Lafleur MA, Tester AM, Thompson EW (2003b) Selective involvement of TIMP-2 in the second activational cleavage of pro-MMP-2: refinement of the pro-MMP-2 activation mechanism. FEBS Lett 553: 457-463
25. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN, Rutschman R, Murray PJ (2003) SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol 4: 546-550
26. Li M, Liu X, Robinson G, Bar-Peled U, Wagner KU, Young WS, Hennighausen L, Furth PA (1997) Mammary-derived signals activate programmed cell death during the first stage of mammary gland involution. Proc Natl Acad Sci USA 94: 3425-3430
27. Lindeman GJ, Wittlin S, Lada H, Naylor MJ, Santamaria M, Zhang JG, Starr R, Hilton DJ, Alexander WS, Ormandy CJ, Visvader J (2001) SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev 15: 1631-1636
28. Liu X, Robinson GW, Hennighausen L (1996) Activation of Stat5a and Stat5b by tyrosine phosphorylation is tightly linked to mammary gland differentiation. Mol Endocrinol 10: 1496-1506
29. Lund LR, Romer J, Thomasset N, Solberg H, Pyke C, Bissell MJ, Dano K, Werb Z (1996) Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 122: 181-193
30. Marine JC, McKay C, Wang D, Topham DJ, Parganas E, Nakajima H, Pendeville H, Yasukawa H, Sasaki A, Yoshimura A, Ihle JN (1999) SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 98: 617-627
31. Matsumoto A, Seki Y, Kubo M, Ohtsuka S, Suzuki A, Hayashi I, Tsuji K, Nakahata T, Okabe M, Yamada S, Yoshimura A (1999) Suppression of STAT5 functions in liver, mammary glands, and T cells in cytokine-inducible SH2-containing protein 1 transgenic mice. Mol Cell Biol 19: 6396-6407
32. Mitchell KO, Ricci MS, Miyashita T, Dicker DT, Jin Z, Reed JC, El-Deiry WS (2000) Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res 60: 6318-6325
33. Mott JD, Werb Z (2004) Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 16: 558-564
34. Nakamura K, Nonaka H, Saito H, Tanaka M, Miyajima A (2004) Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39: 635-644
35. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, Zhang JG, Silva A, Asimakis M, Farley A, Nash AD, Metcalf D, Hilton DJ, Nicola NA, Baca M (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci USA 97: 6493-6498
36. Pezet A, Favre H, Kelly PA, Edery M (1999) Inhibition and restoration of prolactin signal transduction by suppressors of cytokine signaling. J Biol Chem 274: 24497-24502
37. Philp JA, Burdon TG, Watson CJ (1996) Differential activation of STATs 3 and 5 during mammary gland development. FEBS Lett 396: 77-80
38. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V (1993) c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif. Cell Growth Differ 4: 57-65
39. Richards CD, Shoyab M, Brown TJ, Gauldie J (1993) Selective regulation of metalloproteinase inhibitor (TIMP-1) by oncostatin M in fibroblasts in culture. J Immunol 150: 5596-5603
40. Robb L, Boyle K, Rakar S, Hartley L, Lochland J, Roberts AW, Alexander WS, Metcalf D (2005) Genetic reduction of embryonic leukemia-inhibitory factor production rescues placentation in SOCS3-null embryos but does not prevent inflammatory disease. Proc Natl Acad Sci USA 102: 16333-16338
41. Roberts AW, Robb L, Rakar S, Hartley L, Cluse L, Nicola NA, Metcalf D, Hilton DJ, Alexander WS (2001) Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci USA 98: 9324-9329
42. Schmitz J, Weissenbach M, Haan S, Heinrich PC, Schaper F (2000) SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J Biol Chem 275: 12848-12856
43. Schorr K, Li M, Bar-Peled U, Lewis A, Heredia A, Lewis B, Knudson CM, Korsmeyer SJ, Jager R, Weiher H, Furth PA (1999) Gain of Bcl-2 is more potent than bax loss in regulating mammary epithelial cell survival in vivo. Cancer Res 59: 2541-2545
44. Selbert S, Bentley DJ, Melton DW, Rannie D, Lourenco P, Watson CJ, Clarke AR (1998) Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgenic Res 7: 387-396
45. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE (2006) Generation of a functional mammary gland from a single stem cell. Nature 439: 84-88
46. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T (1999) Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity 11: 709-719
47. Soriano P (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70-71
48. Stewart TA, Pattengale PK, Leder P (1984) Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627-637
49. Stross C, Radtke S, Clahsen T, Gerlach C, Volkmer-Engert R, Schaper F, Heinrich PC, Hermanns HM (2006) Oncostatin M receptor-mediated signal transduction is negatively regulated by suppressor of cytokine signaling (SOCS) 3 through a receptor tyrosine-independent mechanism. J Biol Chem 281: 8458-8468
50. Sum EY, Shackleton M, Hahm K, Thomas RM, O'Reilly LA, Wagner KU, Lindeman GJ, Visvader JE (2005) Loss of the LIM domain protein Lmo4 in the mammary gland during pregnancy impedes lobuloalveolar development. Oncogene 24: 4820-4828
51. Sutherland KD, Lindeman GJ, Choong DY, Wittlin S, Brentzell L, Phillips W, Campbell IG, Visvader JE (2004) Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23: 7726-7733
52. Takahashi Y, Carpino N, Cross JC, Torres M, Parganas E, Ihle JN (2003) SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J 22: 372-384
53. Tam SP, Lau P, Djiane J, Hilton DJ, Waters MJ (2001) Tissue-specific induction of SOCS gene expression by PRL. Endocrinology 142: 5015-5026
54. Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, Machii T, Pestell RG, Kanakura Y (2002) E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell 9: 1017-1029
55. Tonko-Geymayer S, Goupille O, Tonko M, Soratroi C, Yoshimura A, Streuli C, Ziemiecki A, Kofler R, Doppler W (2002) Regulation and function of the cytokine-inducible SH-2 domain proteins, CIS and SOCS3, in mammary epithelial cells. Mol Endocrinol 16: 1680-1695
56. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, Hennighausen L (1997) Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 25: 4323-4330
57. Wintermantel TM, Mayer AK, Schutz G, Greiner EF (2002) Targeting mammary epithelial cells using a bacterial artificial chromosome. Genesis 33: 125-130
58. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, Wakioka T, Ohtsuka S, Imaizumi T, Matsuda T, Ihle JN, Yoshimura A (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J 18: 1309-1320
59. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D, Hanada T, Takeda K, Akira S, Hoshijima M, Hirano T, Chien KR, Yoshimura A (2003) IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol 4: 551-556
60. Zhao L, Hart S, Cheng J, Melenhorst JJ, Bierie B, Ernst M, Stewart C, Schaper F, Heinrich PC, Ullrich A, Robinson GW, Hennighausen L (2004) Mammary gland remodeling depends on gp130 signaling through Stat3 and MAPK. J Biol Chem 279: 44093-44100
61. Zhao L, Melenhorst JJ, Hennighausen L (2002) Loss of interleukin 6 results in delayed mammary gland involution: a possible role for mitogen-activated protein kinase and not signal transducer and activator of transcription 3. Mol Endocrinol 16: 2902-2912